Atara Biotherapeutics Securities Class Action
Analysis based on 58 articles · First reported Apr 01, 2026 · Last updated May 07, 2026
The class action lawsuit against Atara Biotherapeutics for alleged misleading statements regarding its drug approval prospects and manufacturing issues is likely to negatively impact its stock price and investor confidence. The legal proceedings could result in significant financial liabilities for Atara Biotherapeutics, while Rosen Law Firm stands to gain from a successful outcome.
Rosen Law Firm has filed a class action lawsuit against Atara Biotherapeutics, alleging that the company made false and misleading statements to investors between May 20, 2024, and January 9, 2026. The lawsuit claims that Atara Biotherapeutics overstated the regulatory prospects of its drug tabelecleucel, failing to disclose manufacturing issues and deficiencies in the ALLELE study that made United States — Food and Drug Administration approval unlikely. These issues also allegedly exposed Atara Biotherapeutics to heightened regulatory scrutiny and jeopardized its clinical trials, ultimately impacting its business and financial condition. Rosen Law Firm, with attorneys Philip Kim and Lawrence Rosen, is encouraging investors who purchased Atara Biotherapeutics securities during the specified period to join the class action, with a lead plaintiff deadline of May 22, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard